

ondine



For Immediate Release

Periowave™ Gum Disease Treatment Studies to be Presented at AADR Annual Meeting

Vancouver, Canada – March 27, 2008 - Ondine Biopharma Corporation (TSX: OBP; AIM: OBP; the “Company”), a medical technology company developing photodisinfection-based products, today announced that the results of two studies using the Periowave™ Photodisinfection System will be presented at the American Association for Dental Research (AADR) Annual Meeting, April 2-6, 2008 in Dallas, Texas. The studies provide evidence of the safety and efficacy of Periowave™ as a treatment for periodontal diseases.

The first study examined the use of Periowave™ on dental implants. This study showed that Periowave™ treatment of the surfaces of dental implants effectively eradicated dense biofilms of the oral bacterium *Porphyromonas gingivalis*, without altering surface metal chemistry of the implant. Periopathogens like *P. gingivalis* are often responsible for failures of these implants, resulting in costly reparative procedures. The second abstract discussed the previously announced meta-analysis of three clinical trials utilizing the Periowave™ Photodisinfection System for the treatment of chronic periodontitis.

“The inclusion of our abstracts in this year’s AADR meeting is an important accomplishment for our Company as it reflects the high quality of research and the dental community’s interest in our Photodisinfection technology,” said Carolyn Cross, President & CEO of Ondine Biopharma.

The following two abstracts are scheduled to be presented:

Abstract: 0942

Periowave eradicates biofilms from dental implants without altering surface chemistry

R.J. Scott *et al.*, Ondine Research Laboratories, Bothell WA

Abstract: 1222

Meta-Analysis of Three Chronic Periodontitis Trials with Periowave™ Photodisinfection

N.G. Loebel, *et al.*, Ondine Research Laboratories, Bothell, WA, USA,

The text of the abstracts and additional information on AADR can be found at www.aadronline.org.

About Periowave™

Periowave™ is a photodisinfection system commercialized by Ondine that utilizes low-intensity lasers and microbiological stains to target and destroy microbial pathogens and reduce the symptoms of disease. The photodisinfection technology was developed by Professor Michael Wilson and colleagues at the Eastman Dental Institute, University College London, and licensed to Ondine by UCL Business plc, University College London. Periowave™ is currently approved in Canada and the European Union for several oral indications. Additional information about Periowave™ is available at www.periowave.com

About Ondine Biopharma Corporation

Ondine is developing non-antibiotic therapies for the treatment of a broad spectrum of bacterial, fungal and viral infections. The Company is focused on creating and commercializing leading edge products utilizing its patented light-activated technology. Photodisinfection provides broad-spectrum antimicrobial efficacy without encouraging the formation and spread of antibiotic resistance. The Company is headquartered in Vancouver, British Columbia, Canada, with a research laboratory in Bothell, Washington, USA, and an international office in St. Michael, Barbados. For additional information, please visit the Company's website at: www.ondinebiopharma.com.

Forward-Looking Statements:

Certain statements contained in this release containing words like "believe", "intend", "may", "expect" and other similar expressions, are forward-looking statements that involve a number of risks and uncertainties. Factors that could cause actual results to differ materially from those projected in the Company's forward-looking statements include the following: market acceptance of our technologies and products; our ability to obtain financing; our financial and technical resources relative to those of our competitors; our ability to keep up with rapid technological change; government regulation of our technologies; our ability to enforce our intellectual property rights and protect our proprietary technologies; the ability to obtain and develop partnership opportunities; the timing of commercial product launches; the ability to achieve key technical milestones in key products and other risk factors identified from time to time in the Company's filings.

The TSX Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

For further information please contact:

Carolyn Cross
President and
Chief Executive Officer
Ondine Biopharma Corporation
(604) 669-0555
ccross@ondinebiopharma.com

Christina Bessant
Investor Relations
The Equicom Group Inc.
(416) 815-0700 ext. 269
cbessant@equicomgroup.com

Irma Gomez-Dib
Media & Investor Relations
FD
(212) 850-5761
Irma.gomez-dib@fd.com

Canaccord Adams Ltd
Nominated Adviser & Broker
Neil Johnson /
Ryan Gaffney
+4420 7050 6500